Showing results (451-460 of 1,393) with videos related to

Sort By:
Pageof 140
JCO Precision Oncology|January 20, 2022
Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical LaboratoriesNatasha B Leighl, Suzanne Kamel-Reid, Parneet K Cheema, et al.
JCO Precision Oncology|January 20, 2022
Implications of Clonal Hematopoiesis for Precision OncologyPeter G Miller, David P Steensma
JCO Precision Oncology|January 20, 2022
A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate CancerSofie H Tolmeijer, Emmy Boerrigter, Jack A Schalken, et al.
JCO Precision Oncology|January 20, 2022
RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal CancerYu Sunakawa, Masato Nakamura, Masahiro Ishizaki, et al.
JCO Precision Oncology|January 20, 2022
Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint BlockadeAndrea Arfè, Geoffrey Fell, Brian Alexander, et al.
JCO Precision Oncology|December 24, 2021
Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported AdequatelyMichael J Grayling, Adrian P Mander
JCO Precision Oncology|September 21, 2022
BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced MelanomaOlivier J van Not, Willeke A M Blokx, Alfons J M van den Eertwegh, et al.
JCO Precision Oncology|October 14, 2022
Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung CancerAaron C Tan, Stephanie P L Saw, Jianbin Chen, et al.
JCO Precision Oncology|October 14, 2022
Risk Stratification of Stage I Grade 3 Endometrioid Endometrial Carcinoma in the Era of Molecular ClassificationWilliam A Zammarrelli, Sarah H Kim, Arnaud Da Cruz Paula, et al.
JCO Precision Oncology|September 14, 2022
Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate CancerJacob E Berchuck, Daniel Boiarsky, Rebecca Silver, et al.
Pageof 140